NCT07229534

Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes

Not Yet Recruiting · Phase 4 · Dong-A ST Co., Ltd. · registry updated 2025-11-17

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin

Inclusion

%≤HbA1c≤10.5% and fasting glucose≤270mg/dL
Treated with 1,000mg/day dose of metformin for at least 8 weeks

Exclusion

Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
eGFR\<45mL/min/1.73m2
ALT and AST 3 times or higher than upper normal range
Determined by investigator as unfit to participate in a clinical trial due to other reasons

Open NCT07229534 on ClinicalTrials.gov All conditions